miR-10b is a prognostic marker in clear cell renal cell carcinoma

Clear cell renal cell carcinoma (ccRCC) is the most common adult kidney cancer. It is an aggressive tumour with unpredictable outcome. The currently used clinical parameters are not always accurate for predicting disease behaviour. miR-10b is dysregulated in different malignancies including RCC.

We assessed the clinical utility of miR-10b as a prognostic marker in 250 patients with primary ccRCC. We examined the correlation between miR-10b and clinicopathological parameters. We compared miR-10b expression among different RCC subtypes and normal kidney tissue.

We observed a stepwise decrease of miR-10b expression from normal kidney to primary ccRCC and a further decrease from primary to metastatic RCC. miR-10b expression was significantly lower in stages III/IV compared with stages I/II (p=0.038). Using a binary cut-off, miR-10b-positive patients had significantly longer disease-free survival (HR=0.47, CI 0.28 to 0.79, p=0.004). In the subgroup of patients with tumour size >4 cm, higher miR-10b expression was associated with significant longer disease-free and overall survival (p=0.001 and p=0.036, respectively). miR-10b was significantly downregulated in ccRCC compared with normal kidney (p<0.0001), and oncocytoma (p=0.031). It was also downregulated in chromophobe RCC. In addition, we identified a number of miR-10b-predicted targets and pathways that are involved in tumourigenesis.

Our data point to miR-10b as a promising prognostic marker in ccRCC with potential therapeutic applications.

Journal of clinical pathology. 2017 Mar 30 [Epub ahead of print]

Heba W Z Khella, Nicole Daniel, Leza Youssef, Andreas Scorilas, Roy Nofech-Mozes, Lorna Mirham, Sergey N Krylov, Evi Liandeau, Adriana Krizova, Antonio Finelli, Yufeng Cheng, George M Yousef

Department of Laboratory Medicine, Keenan Research Centre for Biomedical Science at the Li Ka Shing Knowledge Institute, St Michael's Hospital, Toronto, Canada., Department of Biochemistry and Molecular Biology, University of Athens, Athens, Greece., Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada., Department of Chemistry, Centre for Research on Biomolecular Interactions, York University, Toronto, Ontario, Canada., Department of Chemistry, University of Athens, Athens, Greece., Division of Urologic Oncology, Department of Surgery, Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada., Department of Radiation Oncology, Qilu Hospital of Shandong University, Jinan, Shandong, China.